Showing posts with label dabigatran. Show all posts
Showing posts with label dabigatran. Show all posts
Tuesday, April 03, 2012
Medscape: Bleeding Rates and Medical Costs of New Oral Anticoagulants (warfarin, dabigatran...)
Bleeding Rates and Medical Costs of New Oral Anticoagulants
April 2, 2012 (Chicago, Illinois) — Firsthand experience with the new oral anticoagulants, coupled with excitement over those yet to be widely in use, has inspired a range of studies examining real-world risk/benefits, as well as the potential costs of replacing warfarin with the new agents.
In a poster session at last week's American College of Cardiology 2012 Scientific Sessions, investigators presented two separate experiences with dabigatran from different US centers--showing very different results--while others presented new cost analyses comparing different oral agents with warfarin.
One US report of patients switched to dabigatran showed a much higher rate of major bleeding than in the RE-LY trial, but a lower rate of dyspepsia, while a second report showed a lower rate of both major and minor bleeding compared with RE-LY trial.
add your opinions
anticoagulants
,
bleeding
,
dabigatran
,
oral
,
warfarin
Thursday, January 26, 2012
Subscribe to:
Posts
(
Atom
)